chrisvoncsefalvay/vaers-outcomes huggingface dataset:
diagnosed with CoVID positive; diagnosed with CoVID positive; mild symptoms of cold and congestion; mild symptoms of cold and congestion; This is a spontaneous report from a contactable Other HCP (patient). A 36-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EH9899), Expiration date: Unknown) via intramuscular route of administration in the left arm on 20Jan2021 at 15:45 (at the age of 36-year-old) as a single dose for COVID-19 immunization. The patient's medical history was not reported. The patient had no allergies. Concomitant medication includes Levothyroxine 5 mg. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Dec2021 patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK9231), via an intramuscular route of administration in the right arm on 30Dec2020 at 15:00. On 10Mar2021 at 12:300 patient was diagnosed with Covid positive. Patient have mild symptoms of cold and congestion. The patient did not receive any treatment for the events. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot number cannot be obtained.; Sender's Comments: Considering a plausible temporal relationship and known product safety profile, a possible contributory role of suspect product BNT162B2 to the reported 'COVID 19' cannot be completely excluded.
This spontaneous report as received from an office manager refers to an unknown number of patients of unknown demographics. The patient's current conditions or medical history were not reported. On an unknown date, since December 2013, an unspecified number of patients had been administered PEDVAXHIB (dose, route, lot number and expiration date were not reported) and Td that had been improperly stored. No adverse effect reported. This is one of several reports from the same source. Additional information has been requested.
Initially had some pain into her left neck, then developed severe swelling with CT scan showing inflammation/infection of parotid gland on ipsilateral side she received the vaccine
RT deltoid immediate swelling w/redness, tender to the touch - Ice was applied, recommended to keep an eye.
This 15-month-old child received MMR 05/99. Four months post vax, he developed experienced idiopathic thrombocytopenic purpura  and was hospitalized. According to the pt's mother, however, the even occurred 2 weeks post vax. The reporting physician felt that the event was not related to the vax. Additional information has been requested. Follow-up was received from a physician which indicated "the pt received the vax 4-5 months prior to the development of idiopathic thrombocytopenic purpura - therefore no relationship.
BEXSERO given 3/9/17 -  had sore arm x 1 week other side effects. 3/21 patches macular fine pink, rash forearms waist and lower extremities. Slightly itchy - resolving on 3/22/17. No other symptoms.
Injection site redness in large patch that is hot to the touch and burns; Injection site redness in large patch that is hot to the touch and burns; Injection site redness in large patch that is hot to the touch and burns; Breastfeeding my 6.5 month baby; Breastfeeding my 6.5 month baby; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 33 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 14Apr2021 17:30 (Lot number: EW0158) at the age of 33 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Breast feeding" (ongoing), notes: Breastfeeding 6.5-month baby; "Psoriasis" (unspecified if ongoing); "Crohn's disease" (unspecified if ongoing), notes: Chrone's disease. Concomitant medication(s) included: MESALAMINE. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: ER8730; Administration site: Arm Left; Administration time: 09:00; Events: off label use and drug use in unapproved population.), administration date: 24Mar2021, when the patient was 33 years old, for COVID-19 immunisation, reaction(s): "Off label use". The following information was reported: VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE WARMTH (non-serious), VACCINATION SITE PAIN (non-serious) all with onset 17Apr2021 12:15, outcome "not recovered" and all described as "Injection site redness in large patch that is hot to the touch and burns"; OFF LABEL USE (non-serious), PRODUCT USE ISSUE (non-serious) all with onset 14Apr2021 17:30, outcome "unknown" and all described as "Breastfeeding my 6.5 month baby". Therapeutic measures were not taken as a result of vaccination site erythema, vaccination site warmth, vaccination site pain.  Additional information: The patient had no known allergies to medications, food, or other products. The patient had received no other vaccines within 4 weeks prior to COVID-19 vaccination. The patient had not diagnosed with COVID-19 prior vaccination and Since the vaccination, the patient had not been tested for COVID-19. It was reported that the patients concomitant medications included IUD (intrauterine contraceptive device) (unspecified) for unknown indication from unknown date and unknown if ongoing. The patient reported that these events occurred 67 hours after the second dose injection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  No follow-up attempts are possible. No further information is expected.
Get a lot out when he blows his  nose; Sinus are blocked out; Congestion; Dry rusty cough; 99.1 degrees Fahrenheit fever; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (Get a lot out when he blows his  nose), SINUS CONGESTION (Sinus are blocked out), NASAL CONGESTION (Congestion), COUGH (Dry rusty cough) and PYREXIA (99.1 degrees Fahrenheit fever) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-May-2021, the patient experienced RHINORRHOEA (Get a lot out when he blows his  nose), SINUS CONGESTION (Sinus are blocked out), NASAL CONGESTION (Congestion), COUGH (Dry rusty cough) and PYREXIA (99.1 degrees Fahrenheit fever). At the time of the report, RHINORRHOEA (Get a lot out when he blows his  nose), SINUS CONGESTION (Sinus are blocked out), NASAL CONGESTION (Congestion), COUGH (Dry rusty cough) and PYREXIA (99.1 degrees Fahrenheit fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-May-2021, Body temperature: 99.1 (High) 99.1 degrees Fahrenheit.         Patient reported that he is taking two new medications which one of them is a hormone for cancer.  No treatment information was provided.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 01-Jul-2021: Follow-up received and patient denied further follow up.
The patients did not experience any symptoms; patient was vaccinated with improperly stored varivax; This spontaneous report as received from a medical assistant refers to a 23 months old male patient. The patient's pertinent medical history and drug reactions or allergies were not reported. The patient's concomitant therapy included sterile diluent. On 11-FEB-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) for prophylaxis (strength, dose, route of administration and anatomical location were not reported) of lot # S006647 is an invalid lot number, expiry date reported as 05-MAR-2021 for prophylaxis (product storage error). The patient did not experience any symptoms. The outcome of product storage error was unknown. The temperature excursion for varicella virus vaccine live (oka/merck) (VARIVAX) was reported as -9 degrees Celsius (C) to 8 degrees Celsius (3.3 C) for 53 hours. There was no previous temperature excursion reported. Data logger was involved. No product quality complaint (PQC) was associated with this report.  This is one of the multiple reports from the same reporter.; Sender's Comments:  US-009507513-1911USA011629:
Brought to ED on 5/10/2022 with SOB, covid-19 and hypoxia, SpO2 82%. Report indicated she had been diagnosed Covid-19 about 6 days prior, though the only lab report found was from 5/10/2022. Had prior script for Paxlovid - unclear if she initiated the medication. Report indicated client and family not interested in pursuing Remdesivir treatment and dexamethasone continued. Admitted to hospital 5/10/2022. Discharge date not indicated. Client died 6/4/2022 of Covid-19 pneumonia at nursing home.  Client vaccinated for Covid 19- Moderna:  3/31/2021 008B21A;  5/8/2021 017C21A:  12/9/2021 031H21A Submitter does not have access to further medical records for this client. If more information is needed regarding hospital course, please contact hospital.
All of a sudden his hands swelled up; hand swelling; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (All of a sudden his hands swelled up) and PERIPHERAL SWELLING (hand swelling) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004M20A and 013L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (All of a sudden his hands swelled up) and PERIPHERAL SWELLING (hand swelling). At the time of the report, PERIPHERAL SWELLING (All of a sudden his hands swelled up) and PERIPHERAL SWELLING (hand swelling) outcome was unknown.            patient have a event sore hand after taking the 2nd dose.  No concomitant medications reported by investigator.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.
Vial's use by date was 4/22/22 and the vaccine was administered 4/23/22. No adverse reactions reported
missed the second dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (missed the second dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in March 2021.    On 27-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (missed the second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (missed the second dose) had resolved.            No concomitant medication was provided.
Intense and constant headache, pain is concentrated just by the lower back of the skull and she described it like a hammer hitting her head all day. The pain tends to migrate to the upper side  to the neck. The pain is affecting her sleeping pattern, such as the heavy medicación she needs to Take is not enought to keep her sleep constinusly during the night.
This case was reported by a other health professional via call center representative and described the occurrence of injection site erythema in a 16-year-old male patient who received BEXSERO (batch number 16B101, expiry date unknown). Concomitant products included GARDASIL and MENACTRA. On 15th August 2017, the patient received the 1st dose of BEXSERO. On 16th August 2017, 1 days after receiving BEXSERO, the patient experienced injection site erythema. On an unknown date, the outcome of the injection site erythema was recovered/resolved. It was unknown if the reporter considered the injection site erythema to be related to BEXSERO. Additional details were reported as follows: This case was reported by a medical assistant. On 15th August 2017, the patient received 2nd doses of GARDASIL (batch number: N012043) and MENACTRA (batch number: U5823AB). The patient was not new to these vaccines and did not had a reaction to them. After about 24 hours of vaccination, the patient experienced a 6 by 8 cm erythema at the site of injection. The erythema was not hot to touch. The event lasted a few days. The reporter was transferred to medical information for questions on whether the patient could receive another dose of BEXSERO.
Left arm swelled from shoulder to below the elbow, it was so sore could not move arm at all.  Lasted for 12 hours, still sore the next day but could move arm. Felt chilled and weak.  I used an ice pack off and on through most of the evening.
Pt. received VARIVAX instead of Zoster as order by provider. Age of patient at time of event: 65 years.
I received the J&J vaccination on 3/29/2021. 4-5 hours after receiving the Moderna booster, I suddenly came down with a very sore throat. The pain is mostly when I swallow. This is similar to my first COVID-19 symptom when I contracted it in May of this year.
Started within third day after vaccination w Itching mid back around to mid front lower torso area, few red raised areas; no topical creams or ointment relieved symptoms which worsened over the course of several days.  Dr, appt on 2/3/2021 diagnosed as shingles and is being treated with Valacyclovir HCL, 1 gram two times/day for 7 days.
sore arm muscle; sore arm muscle; Social problem; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of bursitis (received 1st dose on September 2019 (refer case ID:US2020118935)).   On 10th July 2020, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 weeks after receiving Shingrix, the patient experienced injection site pain, myalgia and social problem. On an unknown date, the outcome of the injection site pain and myalgia were recovered/resolved and the outcome of the social problem was unknown.   It was unknown if the reporter considered the injection site pain and myalgia to be related to Shingrix.  Additional details were provided as follows: The patient received her first Shingrix dose in September 2019 and had not received the second shingrix dose because her pharmacy was not administering it because of COVID-19. The pharmacy was not planning to get 2nd Shingrix vaccine. The patient received the 2nd Shingrix vaccine on 10th July 2020. There were no adverse reactions except for a slightly sore arm muscle where the shot received. The adverse event lasted for less than 3 days. At the time of reporting patient did not experienced adverse event. The would be contacting to make an appointment and patient like to know how long to wait.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020118935:same reporter
Fatigue; Arm was sore; Headache; Nausea; Diarrhea; This is a spontaneous report from a contactable consumer reported for herself. A 22-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EM9810, Expiration date: unknown), via an unspecified route of administration, administered in the left arm on 29Jul2021 (age at vaccination was 22 years) as dose 1, single for COVID-19 immunization. The patient's medical history included none from an unknown date. There were no concomitant medications reported. On 30Jul2021, after the first dose the patient experienced fatigue, arm was sore, headache, nausea and diarrhea. The side effects went away on 01Aug2021. Patient started having side effects again on 05Aug2021. Patient began with a headache yesterday. Then on 06Aug2021, Patient started having headache, nausea, diarrhea, and fatigue. They all came back the same. Patient was on no other medications. Patient has not gone to the doctor, but she was going to call the doctor after this. The outcome of event arm was sore was unknown. The outcome of event fatigue, headache, nausea and diarrhea was not recovered.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
At 3:17 PM child had a petit mal seizure lasting appx 30 sec; at 9:30 PM she had 3 grand mal seizures each lasting 15-20 seconds each.
Right anterolateral thigh: 6 x 6 cm induration. Left anterolateral thigh: 9 x 7 cm induration.
What to do when I have a fever as a side effect; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (What to do when I have a fever as a side effect) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (What to do when I have a fever as a side effect). At the time of the report, PYREXIA (What to do when I have a fever as a side effect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported by the reporter.  No Treatment information was provided by the reporter.
Exposed some time between July 8-11 (Family gathering) July 12, AM-Headache. Took Sudafed and ibuprofen. Headache cleared up. Tested negative for Covid-19 July 13, woke with sore throat. Took ibuprofen. Sore throat went away. Tested negative for Covid-19 July 14, woke with sore throat. Took ibuprofen. Sore throat went away. Tested positive for Covid-19.  July 15, no symptoms except started to get dry cough and felt a little achy. Sister (vaccinated/single boosted), who tested positive at the same time, had gone into ER, so I called my doctor, who prescribed Paxlovid. Started taking it in the evening. Nurse suggested I stop taking CBD and Ashwaganda while on Paxlovid. No side effects except bitter taste in mouth. July 16, slight dry cough, low grade fever. Took ibuprofen and Benadryl (as sleep aid) July 17, slight dry cough. Took ibuprofen and Benadryl (as sleep aid) July 18, no symptoms. Took Benadryl (as sleep aid) July 19, no symptoms. Took Benadryl (as sleep aid) July 20, no symptoms. Finished Paxlovid in the morning. Tested negative for Covid-19 July 23, tested negative for Covid-19 July 25, tested negative for Covid-19 July 28, tested negative for Covid-19 August 1, tested negative for Covid-19
7/16/07 - Developed severe case of pneumonia with fever - no cough or cold prior.  Was sent to hospital for chest x-ray.  Was given inhalation therapy and prescribed cefdinir (300mg) and albuterol (90mg).  7/16/07 evening - went to emergency room when patient couldn't breath.  Received inhalation therapy and z-pak  7/18/07 - checked at doctors' office for improvement 7/19/07 - was given additional albuterol (.83mg) and told to use one vial every 4 hours.   7/07 - given refill of z-pak.  9/28/07 - sinus infection and fever (has had for about 3 weeks) and is prescribed Z-pak  9/07 - begins losing substantial amounts of hair that continues for approximately 4 months.  3/7/08 - is seen for ear and sinus infection and fever and prescribed z-pak  12/19/08 - patient develops flu-like symptoms with vomiting, diarrhea, and fever.  Is given phenergan (25 mg).  Is sent to hospital when vomiting continues.  Is given 3 bags of IV fluid and treated for vomiting and diarrhea.  1/20/09 - develops cold symptoms and fever.  Chronic bruising.  2/13/09 Received ER medical records of 7/17/2007. FINAL DX: LLL pneumonia Records reveal patient experienced fever, cough, difficulty breathing, SOB.  Had been seen by PCP 7/16 & dx w/pneumonia.  Antibiotics & inhaler had not improved s/s.  Exam revealed decreased LLL breath sounds.  Tx w/nebs, IVF & oral antibiotics.
First dose / on November 6th 2019 / second dose / not / administered yet; This case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 6th November 2019).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable to this report. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter did not consent to follow up.
I went into Atrial Fibrillation witching 16-20 minutes of administration , my Watch picked it up. I since then have been developing palpitations and chest pain.
flue like symptoms the day after shot.  Then weekly for four or five hours each week after shot.  Usually six to eight days apart.  Chills and muscle pain.  low fever when checked.  Treated with pain medication, ibuprofen, etc.    First week was Wednesday March 3.  other weeks were on Wednesday, Thursday, or Friday.  Only once a week.  Last night episode occurred, Wednesday April 14.  I do not think any weeks were skipped.  The last two episodes were milder.    I also have mild headaches and mild balance issues.  I had covid the last of December.  It is possible that the headaches and balance issues are from that.
Her arm swelled very large as soon as I finished injection. I gave her an ice pack, a 10mg loratadine, and 2 ibuprofen 200mg tabs. She sat for 15 minutes swelling had gone down slightly at that time.
Employees vaccinated from a vial that was punctured more than 6 hours ago; A spontaneous report was received from a nurse concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the event, expired product administered.  The patient's medical history was not provided. Concomitant product use was not provided by the reporter.   On 23 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot # 011J20A) for prophylaxis of COVID-19 infection.  On 27 Dec 2020, the nurse reported that the Moderna COVID-19 vaccine was given out on 23 Dec 2020 and 24 Dec 2020 with doses from a vial that had been punctured for more than 6 hours instead of being discarded. She stated that the punctured vials were placed in the fridge or on top of an ice pack or in the carton and used beyond 6 hours after it was first punctured. No other specific details were provided. Treatment information was not provided.   Action taken with mRNA-1273 in response to the event was not provided.   The event, expired product administered, was considered resolved on 23 Dec 2020.; Reporter's Comments: This case concerns an unidentified patient who received their first of two planned doses of mRNA-1273 (Lot 011J20A), reporting Expired product administered without any associated adverse events.
Woke up next morning around 6a to racing and irregular heart beat, sweating, nausea and diarrhea. Those symptoms persisted for about 24 hours. Intermittent chest pains have been present ever since, lessening in frequency though.